The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2025

Global Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1896931

No of Pages : 84

Ask Your Query

Synopsis

Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.

The global Prostate Cancer Nuclear Medicine Diagnostics market was valued at US$ 720 million in 2023 and is anticipated to reach US$ 1449.6 million by 2030, witnessing a CAGR of 10.6% during the forecast period 2024-2030.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Nuclear Medicine Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Nuclear Medicine Diagnostics.

Report Scope

The Prostate Cancer Nuclear Medicine Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Cancer Nuclear Medicine Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Prostate Cancer Nuclear Medicine Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List):

  • Blue Earth Diagnostics
  • PETNET Solutions
  • Cardinal Health
  • Lantheus Medical Imaging
  • Jubilant Pharma
  • NCM-USA
  • Progenics Pharma
  • Telix Pharma
  • ImaginAb
  • Theragnostics
  • Novartis
  • Alliance Medical

Segment by Type

  • SPECT
  • PET

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Nuclear Medicine Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 SPECT
1.2.3 PET
1.3 Market by Application
1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Perspective (2019-2030)
2.2 Prostate Cancer Nuclear Medicine Diagnostics Growth Trends by Region
2.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Prostate Cancer Nuclear Medicine Diagnostics Market Dynamics
2.3.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Trends
2.3.2 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
2.3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
2.3.4 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue
3.1.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Nuclear Medicine Diagnostics Revenue
3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio
3.4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2023
3.5 Prostate Cancer Nuclear Medicine Diagnostics Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
3.7 Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Type
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2025-2030)
5 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Application
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2019-2030)
6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2019-2024)
6.4 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size (2019-2030)
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2019-2024)
7.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2019-2030)
9.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Blue Earth Diagnostics
11.1.1 Blue Earth Diagnostics Company Detail
11.1.2 Blue Earth Diagnostics Business Overview
11.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.1.5 Blue Earth Diagnostics Recent Development
11.2 PETNET Solutions
11.2.1 PETNET Solutions Company Detail
11.2.2 PETNET Solutions Business Overview
11.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.2.5 PETNET Solutions Recent Development
11.3 Cardinal Health
11.3.1 Cardinal Health Company Detail
11.3.2 Cardinal Health Business Overview
11.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.3.5 Cardinal Health Recent Development
11.4 Lantheus Medical Imaging
11.4.1 Lantheus Medical Imaging Company Detail
11.4.2 Lantheus Medical Imaging Business Overview
11.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.4.5 Lantheus Medical Imaging Recent Development
11.5 Jubilant Pharma
11.5.1 Jubilant Pharma Company Detail
11.5.2 Jubilant Pharma Business Overview
11.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.5.5 Jubilant Pharma Recent Development
11.6 NCM-USA
11.6.1 NCM-USA Company Detail
11.6.2 NCM-USA Business Overview
11.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.6.5 NCM-USA Recent Development
11.7 Progenics Pharma
11.7.1 Progenics Pharma Company Detail
11.7.2 Progenics Pharma Business Overview
11.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.7.5 Progenics Pharma Recent Development
11.8 Telix Pharma
11.8.1 Telix Pharma Company Detail
11.8.2 Telix Pharma Business Overview
11.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.8.5 Telix Pharma Recent Development
11.9 ImaginAb
11.9.1 ImaginAb Company Detail
11.9.2 ImaginAb Business Overview
11.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.9.5 ImaginAb Recent Development
11.10 Theragnostics
11.10.1 Theragnostics Company Detail
11.10.2 Theragnostics Business Overview
11.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.10.5 Theragnostics Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.11.5 Novartis Recent Development
11.12 Alliance Medical
11.12.1 Alliance Medical Company Detail
11.12.2 Alliance Medical Business Overview
11.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2019-2024)
11.12.5 Alliance Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock